SmallCaps
ASX:GSSPharmaceuticals, Biotechnology & Life SciencesLife Sciences Tools & Services

Genetic Signatures Ltd

$0.080
+$0.007 (+9.59%)
Day Range
$0.075 – $0.080
52 Week Range
$0.051 – $0.430
Volume
1.52M
Avg Volume (10D)
303.82K
Market Cap
$18.17M

Price Chart

OHLC · volume · moving averages

$0.080-$0.020 (-20.00%)over 6M
Hi$0.205Lo$0.051
Price-sensitive newsVolumePrev close · 52W range

Market Statistics

Today's trading range

Open
$0.075
Previous Close
$0.073
Day High
$0.080
Day Low
$0.075
52 Week High
$0.430
52 Week Low
$0.051

Valuation

Fundamental multiples

Market Cap
18.17M
Shares Outstanding
227.14M
Price to Book
0.38

Trading Activity

Volume & order book

Volume
1.52M
Value Traded
120.23K
Bid
$0.081 × 8,000
Ask
$0.087 × 12,000

Performance

Returns across timeframes

1 Day
7.35%
5 Day
23.73%
13 Week
0.00%
52 Week
-75.25%
YTD
-70.80%

Technical Indicators

Momentum & moving averages

RSI (14)
74.81
50-Day SMA
$0.063
200-Day SMA
$0.127

— From the desk

Latest News

Genetic Signatures Inks 10-Year Danish Supply Deal for GI Screening Technology
Biotechnology

Genetic Signatures Inks 10-Year Danish Supply Deal for GI Screening Technology

GSS signs 10-year Danish deal with Hvidovre Hospital for EasyScreen Pan-Enteric; boosts recurring revenue, EMEA growth; first-year 28k samples from Sept 2026.

Genetic Signatures Reports Regional Success of EasyScreen Gastrointestinal Parasite Detection Kit
Biotechnology

Genetic Signatures Reports Regional Success of EasyScreen Gastrointestinal Parasite Detection Kit

Genetic Signatures (ASX: GSS) has reported a strong start to the new financial year with the commercial success of its EasyScreen gastrointestinal parasite detection testing kit across all operating regions, and a 20% increase in sales for the quarter to $5.4 million. Revenue contributions came from new business with existing customers in Australia, which experienced […]

ASX biotech stocks benefiting from the COVID-19 story
Biotechnology

ASX biotech stocks benefiting from the COVID-19 story

Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Naturally, the biotechs drawing a connection with fighting or detecting the virus – spurious or otherwise – have seen their valuations soar. Not that investor interest is […]

Genetic Signatures applies to market coronavirus test kit throughout UK and EU
Biotechnology

Genetic Signatures applies to market coronavirus test kit throughout UK and EU

Molecular diagnostics company Genetic Signatures (ASX: GSS) has submitted a European CE in vitro diagnostics registration application for its new 3base EasyScreen coronavirus detection kit. The kit complements the company’s existing EasyScreen respiratory pathogen detection kit which identifies 14 common respiratory pathogens including influenza A and B, rhinovirus and M. pneumoniae and allows a large […]